1. Managing Hard-To-Treat Hypertension: What Every Physician Should Know

3. Introduction/Background

4. ESH/ESC 2013 and JNC8 Blood Pressure Treatment Recommendations

5. Cardiovascular Risk Stratification in Patients with Hypertension

6. Resistant HTN and Hard-to-Treat HTN

7. CV Risk Factors That May Complicate HTN Treatment

8. Results From The SPRINT Trial: Lower SBP Target With Intensive Treatment Reduces Events

9. Controversy Surrounding BP Measurement in SPRINT

10. The J-Curve and Risk of Aggressive Blood Pressure Reduction

11. Early, Aggressive Treatment of HTN?

12. HTN Treatments and Treatment Combinations

13. Non-Adherence to Antihypertensive Agents: Results of a Urine-Based Assay

14. Single-Pill Combinations vs Free Drug Components: Effects on Compliance

15. The Treatment-Resistant Hypertensive Patient

16. (Apparent) Resistant HTN In Patients on Appropriate Triple Therapy

17. Non-Adherence and the Older Hypertensive Patient

18. Improving Adherence to Therapy: Patient Communication Strategies

19. Comorbidities and Complications of HTN

20. End-Organ Damage Associated With Chronic Hypertension

21. The Cardiovascular-Renal Continuum in The Context of Hypertension

22. Prevalence of HTN in Selected AF Trials

23. Antihypertensive Single-Pill Combination Therapy Compared to Monotherapy and Placebo: A Subgroup Analysis

24. Current Dosages of Hydrochlorothiazide for HTN May Be Suboptimal

25. Superior BP Reduction With Initial Combination Therapy

26. Initial Combination HTN Therapy Reduces CV Event Rates

27. Recommendations of Treatment Strategies in Patients With Comorbid Diabetes

28. LEADER: Primary Outcome Liraglutide vs Placebo*

29. EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

30. Summary and Conclusions

31. Abbreviations

32. Abbreviations (cont)